Most Recent
a2 Milk loses challenge to Nestle’s Nan A2 trade mark for baby formula
Intellectual Property 2021-08-04 11:52 am By Cindy Cameronne

New-Zealand dairy company a2 Milk has lost its opposition to registration by food and beverage giant Nestle of its NAN A2 trade mark for infant formula, with a delegate of the Trade Marks Office finding the mark was not substantially identical to a2’s logo.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Sydney Opera House takes China trade group to court for ‘recklessly’ copying logo
Intellectual Property 2021-08-02 1:06 pm By Bianca Hrovat

The Sydney Opera House Trust is suing a China trade group, accusing the organisation of flagrant copyright infringement for reproducing substantial portions of the iconic landmark’s trade mark-protected sail design in its logo.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

‘Why cannot our own creations also create?’: AI can be inventor on patent, court finds
Intellectual Property 2021-07-30 12:39 pm By Cat Fredenburgh

A judge has found artificial intelligence can be named as the inventor on a patent application, setting aside an IP Australia finding that allowing a machine to be considered an inventor would render the Patents Act incapable of “sensible operation”.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Culture Kings steps out of the ring, resolves Mike Tyson suit over ‘misleading’ T-shirts
Intellectual Property 2021-07-29 1:42 pm By Bianca Hrovat

Streetwear retailer Culture Kings has resolved a lawsuit brought by former world boxing champion Mike Tyson alleging the company misled consumers by using his image on its T-shirts.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

In win for Abbey Labs, Elanco’s animal drug patent thrown out for lack of invention
Intellectual Property 2021-07-29 10:16 am By Miklos Bolza

IP Australia has refused to register a patent acquired by Elanco Australasia from Bayer covering a lice treatment, after amendments failed to address findings that the patent lacked an inventive step.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

a2 Milk urges court to register ‘slightly mysterious’ trade marks
Intellectual Property 2021-07-27 5:00 pm By Miklos Bolza

The a2 Milk Company has urged the Federal Court to allow its ‘a2 Milk’ and ‘True a2’ trade marks to be registered, arguing they’re not merely descriptive of a protein in milk.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Tabcorp sued for patent infringement over ‘Cash Out on Quaddie’ feature
Intellectual Property 2021-07-27 3:04 pm By Miklos Bolza

Australian gambling giant Tabcorp has been hit with a lawsuit for allegedly infringing two patents with its ‘Cash Out on Quaddie’ wagering feature.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Seven launches courtroom battle to save ‘7Now’ trade mark
Intellectual Property 2021-07-23 1:58 pm By Cat Fredenburgh

Seven Network has filed Federal Court proceedings after convenience store chain 7-Eleven succeeded in having its ‘7NOW’ trade mark removed for non-use.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Minetek can’t inspect USB devices for potential lawsuit against ex-employee, court rules
Intellectual Property 2021-07-22 10:04 pm By Cindy Cameronne

Global mine technology company Minetek has lost its bid to access USB devices held by equipment manufacturer Howden’s solicitors for use in a potential lawsuit against a former employee who it says may have unlawfully used confidential company information.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

After GetSwift, judge could not hear split trial in Revlimid patent case, court told
Intellectual Property 2021-07-20 8:39 pm By Christine Caulfield

A proposal by Bristol-Myers Squibb-owned Celgene to split a second trial into two more hearings in a dispute over patents covering the pharmaceutical maker’s top selling cancer drug Revlimid would result in wasted costs, wasted time and require a second judge, a court has been told.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?